Lilly’s breast cancer drug gets an edge over Pfizer’s, for now
In a large study, Eli Lilly’s Verzenio decreased the risk of relapse in early-stage breast cancer, making it the first drug of its type to do so and giving it an edge over the market-leading treatment from Pfizer.
But, as STAT’s Matthew Herper reports, that benefit could be short-lived. Lilly’s successful study focused on a select group of high-risk breast cancer patients. Last month, Pfizer’s competing Ibrance failed in a trial that recruited a more diverse group of patients. That means Lilly’s perceived superiority could be a matter of trial design, not having a better drug.
Read more.
But, as STAT’s Matthew Herper reports, that benefit could be short-lived. Lilly’s successful study focused on a select group of high-risk breast cancer patients. Last month, Pfizer’s competing Ibrance failed in a trial that recruited a more diverse group of patients. That means Lilly’s perceived superiority could be a matter of trial design, not having a better drug.
Read more.
.png)
No hay comentarios:
Publicar un comentario